Fundamentals of Decentralized Clinical Trials: Strategy and Execution

Dr. Yang is a Principal Clinical Innovation and Technology Leader in the US Medical Affairs Evidence Generation Team at Genentech. Anna leads discussions related to DCT strategy and implementation with study teams across the portfolio, infusing insights and best practices from industry partners. Anna cares deeply about inspiring change in the lagging adopters by sharing important lessons learned and reshaping assumptions. Anna is also curious about quantifying the value of DCT approaches and is actively involved with DTRA and the Tufts PACT cross-industry collaborations. Anna received her PharmD at the Rutgers Ernest Mario School of Pharmacy and completed a postdoctoral fellowship in the Genentech BioOncology Medical Science Liaisons team.

Dr. Rodriguez-Chavez is a preeminent clinical research and regulatory affairs leader who has forged a distinguished 30-year career in infectious diseases, immunology, oncology, vaccines and rare diseases. His expertise spans the entire medical product lifecycle. Previously Senior Vice President at ICON plc, spearheading DCTs and digital medicine strategies. He is also a former U.S. FDA Senior Official who developed the draft guidance on DCTs with FDA colleagues and made pivotal contributions to modernize clinical research by using digital health technologies (DHTs). He has authored 60+ publications, delivered 151+ global presentations, and his contributions on DCTs and DHTs resonate through industry, academia and non-for-profit enterprises.